Pulse
NIFTY 5024,980.40+0.35%
SENSEX81,720.10+0.28%
NIFTY SHARIAH 254,850.15+0.42%
GOLD 24K (10g)₹75,420+0.38%
SILVER (1kg)₹88,400-0.12%
ACTIVE IPOS8 Open+38% GMP
TCS₹4,124.50+1.18%
INFY₹1,892.40+1.22%
USD/INR₹83.92-0.04%
NIFTY 5024,980.40+0.35%
SENSEX81,720.10+0.28%
NIFTY SHARIAH 254,850.15+0.42%
GOLD 24K (10g)₹75,420+0.38%
SILVER (1kg)₹88,400-0.12%
ACTIVE IPOS8 Open+38% GMP
TCS₹4,124.50+1.18%
INFY₹1,892.40+1.22%
USD/INR₹83.92-0.04%
LAXMI DENTAL LIMITED

LAXMI DENTAL LIMITED

NSE: LAXMIDENTL
Medical Instruments & SuppliesHealthcareSMALL CAPMCap ₹1.02k Cr
₹184.72₹-6.08 (-3.19%)

Market Closed • NSE

Market cap₹1.02k Cr
Enterprise value₹1.04k Cr
P/E TTM32.75
Forward P/E14.60
P/B4.18
EPS TTM₹5.64
Forward EPS₹12.65
ROCE15.00%
D/E5.33
Dividend yield0.00%
Face value₹2.00
52W high₹344.80
52W low₹155.88
Price chart(1Y)
1Y Return:-18.53% (₹42.02)
H: ₹242.5L: ₹182.44
1W-5.62%
1M-6.82%
3M-17.84%
6M-4.82%
1Y-41.14%
Today at a glance

Day range

₹182.44₹194.19

52 week range

₹155.88₹344.80
Volume252.0K3.71x 20D avg
Free float50.00%+271.20% volume

LAXMI DENTAL LIMITED closed at INR184.72 (-3.19%) on volume 3.71x its 20-day average, trading 46.43% below its 52-week high.

Technical analysis
RSI (14)36.0Neutral (30–70)
MACDBEARISHBearish (Below signal)
ATR (14)₹6.58High
SMA 20₹193.96BEARISH
SMA 50₹197.58BEARISH
SMA 100₹210.12BEARISH
SMA 200₹207.01BEARISH
CPR bottom₹193.94
Pivot₹192.89
CPR top₹191.85
What changed recently?

2026-Q2

Q2 FY2026 Financial Results

PAT moved +0% QoQ

Shariah audit
Methodology: AAOIFI Shariah Standard No. 21
PASS4/4 criteria
Shariah Compliant
CriteriaNumeratorDenominatorValueThresholdStatus
Interest-bearing debt ratio₹13.0 Cr₹1.02k Cr1.28%≤ 33%PASS
Non-halal income ratio–₹271.5 Cr0.00%≤ 5%PASS
Illiquid assets ratio₹285.6 Cr₹294.0 Cr97.14%≥ 20%PASS
Receivables ratio–₹294.0 Cr—≤ 49%PASS
Valuation & sector context
MetricCompanySector
P/E32.7537.00
Forward P/E14.60—
P/B4.185.00
EV/EBITDA—18.00
PEG—1.00
Earnings yield3.102.70
Growth & profitability
RevenuePAT
FY25PAT margin 13.10%
FY26PAT margin 10.40%

Revenue and PAT bars use independent scales to make their year-on-year direction readable.

Revenue CAGR 3Y+4.30%
Revenue CAGR 5Y+2.30%
PAT CAGR 3Y-3.30%
PAT CAGR 5Y-1.80%
Operating margin13.44%
Net margin10.76%
Financial health & cash flow
Net debt₹4.6 CrModerate
Interest coverage20.20xEBIT / interest
CFO / PAT-0.17x3Y average
Net debt / EBITDA—Leverage
Operating cash flow₹-499.7 Lakh
Capital expenditure–
Free cash flow₹-2336.8 Lakh
Financial statements

Complete reported financial history · Values use the company's reporting currency

Hover over the chart for exact reported values. Percentage lines use the right-hand axis.

Fundamental scorecard
Overall70/100
Valuation50/100
Profitability65/100
Financial health95/100

A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.

Strengths, risks & investment thesis

Strengths

Low Debt Profile: Debt-to-Equity is comfortable at 0.05x

Risks

Subject to cyclical raw material and macro industry pressures

Bull case

Market Leadership: Established operational scale in Medical Instruments & Supplies.

Bear case

Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.

Flip condition

Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.

Shareholding pattern
Quarterly ownership historyLatest valid period · September 2025

Ownership distribution

Sept 2025Latest holding

Category trends

Hover over a period for exact holdings

60%40%20%0%Jun 2025Sept 2025
40.99%Institutional holding
17.21%Public holding
2Periods available
0.00%Promoter pledged
36.94KShareholders
Delivery participation

Traded volume and delivery percentage across the latest 20 sessions

Average delivery (20D)58.46%+17.35% latest vs average
Highest delivery79.42%on 23 Sept
Average volume (20D)67.9KTrading-session average
Conviction trendStrengthening+17.35% latest reading
Traded volumeDelivery %
Peer comparison

Compare valuation, latest quarterly performance and year-on-year growth

8 companies
Company nameMarket cap ₹ CrP/E ratioDividend yield %Quarterly sales ₹ CrProfit after tax ₹ CrSales growth %Profit growth %
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries LimitedSUNPHARMA
Open analysis
₹4.22L34.900.91%₹15,300.00₹2,901.00+10.46%+26.52%
Divi's Laboratories Limited
Divi's Laboratories LimitedDIVISLAB
Open analysis
₹2.43L82.970.33%₹3,080.00₹902.00+27.80%+65.50%
Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals LimitedTORNTPHARM
Open analysis
₹1.73L72.830.83%₹4,128.00₹389.00+41.90%-21.89%
Apollo Hospitals Enterprise Limited
Apollo Hospitals Enterprise LimitedAPOLLOHOSP
Open analysis
₹1.13L54.320.25%₹7,044.00₹610.00+20.58%+38.32%
Zydus Lifesciences Limited
Zydus Lifesciences LimitedZYDUSLIFE
Open analysis
₹1.12L25.030.09%₹8,017.00₹990.00+21.95%-34.91%
LENSKART SOLUTIONS LTD
LENSKART SOLUTIONS LTDLENSKART
Open analysis
₹1.12L174.730.00%₹2,714.00₹228.00+43.29%+273.77%
Laurus Labs Limited
Laurus Labs LimitedLAURUSLABS
Open analysis
₹1.11L101.830.12%₹2,026.31₹367.60+29.10%+125.49%
Cipla Limited
Cipla LimitedCIPLA
Open analysis
₹1.07L31.780.98%₹7,119.00₹786.00+2.33%-39.16%
About LAXMI DENTAL LIMITED
LAXMI DENTAL LIMITED

Incorporated in 2004, Laxmi Dental is an integrated dental products company offering a comprehensive portfolio of Dental Products[1]

IndiaHealthcare

Questions investors ask
Is LAXMI DENTAL LIMITED Shariah compliant?

LAXMI DENTAL LIMITED is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (1.28%) complies with AAOIFI threshold (≤ 33%).

What is LAXMI DENTAL LIMITED's current valuation relative to peers?

LAXMI DENTAL LIMITED trades at a P/E of 32.8x compared to the sector median of 37x, and a Price-to-Book of 4.2x.

Is the company financially healthy?

The company has a Debt-to-Equity ratio of 0.05x. Interest coverage is 20.2x.

What are the historical revenue and profit growth rates?

Over the past 5 years, revenue compounded at 2.3% while net profit growth averaged -1.8%.

Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.

Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.